Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18499095 | 0.78 | TASP1 (0.63) | TASP1SAE1KMT2AMEN1ALDH1A1 | |
| SCHEMBL9720508 | 0.71 | CA1 (0.73) | TASP1CA1CA2KMT2AMEN1 | |
| SCHEMBL13546159 | 0.71 | MYC (0.69) | TASP1CA1KMT2AMEN1ALDH1A1 | |
| SCHEMBL2174619 | 0.71 | TASP1 (0.55) | TASP1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7120462 | 0.70 | TASP1 (0.54) | TASP1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL956998 | 0.69 | ACP1 (0.65) | TASP1CA1CA2KMT2AMEN1 | |
| SCHEMBL6463656 | 0.69 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2900024 | 0.69 | TASP1 (0.52) | TASP1SAE1ROCK2 | |
| SCHEMBL957161 | 0.68 | KDM4E (0.59) | TASP1CA1CA2KMT2AMEN1 | |
| SCHEMBL6464678 | 0.68 | LMNA (0.63) | TASP1CA1CA2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501811-B2 | TASPASE1 inhibitors and their uses | WASHINGTON UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501811-B2 | TASPASE1 inhibitors and their uses | WASHINGTON UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120015990-A1 | TASPASE1 INHIBITORS AND THEIR USES | THE WASHINGTON UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015990-A1 | TASPASE1 INHIBITORS AND THEIR USES | THE WASHINGTON UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015990-A1 | TASPASE1 INHIBITORS AND THEIR USES | RNASE1, TASP1, PPA1 | TASP1 2/4885CA1 3036/4885CA2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.